Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

Tarik Asselah, Professor of Hepatology at Hôpital Beaujon and University of Paris-Cité; Head of Viral Hepatitis unit at INSERM

“We are seeing rapid viral suppression that deepens over time, alongside improvement in liver fibrosis and function, giving us a more complete view of what sustained control of HDV could mean for patients.”

Tarik Asselah, Professor of Hepatology at Hôpital Beaujon and University of Paris-Cité; Head of Viral Hepatitis unit at INSERM

“Furthermore, the profound antiviral potency with patients achieving virus undetectability provides optimism for the potential of elebsiran and tobevibart to offer finite treatment.”

Tarik Asselah, Professor of Hepatology at Hôpital Beaujon and University of Paris-Cité; Head of Viral Hepatitis unit at INSERM

“As the clinical experience with elebsiran and tobevibart continues to grow, so does our optimism about the possibility to meaningfully change the trajectory of this serious disease.”

David Liu, Chief Medical Officer of Vir Biotechnology

“These preliminary findings show the potential for a finite treatment approach that goes beyond suppressing HDV to potentially achieving cure.”

David Liu, Chief Medical Officer of Vir Biotechnology

“For patients who have faced the prospect of living with this chronic disease, that possibility could fundamentally change what is achievable in hepatitis delta.”